Success Metrics

Clinical Success Rate
80.0%

Based on 48 completed trials

Completion Rate
80%(48/60)
Active Trials
4(5%)
Results Posted
56%(27 trials)
Terminated
12(15%)

Phase Distribution

Ph phase_2
13
16%
Ph not_applicable
9
11%
Ph phase_1
18
22%
Ph phase_3
18
22%
Ph phase_4
15
19%
Ph early_phase_1
5
6%

Phase Distribution

23

Early Stage

13

Mid Stage

33

Late Stage

Phase Distribution78 total trials
Early Phase 1First-in-human
5(6.4%)
Phase 1Safety & dosage
18(23.1%)
Phase 2Efficacy & side effects
13(16.7%)
Phase 3Large-scale testing
18(23.1%)
Phase 4Post-market surveillance
15(19.2%)
N/ANon-phased studies
9(11.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

48 of 64 finished

Non-Completion Rate

25.0%

16 ended early

Currently Active

4

trials recruiting

Total Trials

81

all time

Status Distribution
Active(6)
Completed(48)
Terminated(16)
Other(11)

Detailed Status

Completed48
Terminated12
unknown11
Withdrawn4
Not yet recruiting2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
81
Active
4
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 15 (6.4%)
Phase 118 (23.1%)
Phase 213 (16.7%)
Phase 318 (23.1%)
Phase 415 (19.2%)
N/A9 (11.5%)

Trials by Status

completed4859%
not_yet_recruiting22%
recruiting22%
active_not_recruiting22%
terminated1215%
unknown1114%
withdrawn45%

Recent Activity

Clinical Trials (81)

Showing 20 of 81 trialsScroll for more
NCT02205762Phase 2

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Active Not Recruiting
NCT02858310Phase 1

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Completed
NCT05538247Early Phase 1

Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function

Recruiting
NCT02950259Phase 1

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Completed
NCT05035407Phase 1

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Terminated
NCT07218653Early Phase 1

Sex-Specific Cerebrovascular Dysfunction in Metabolic Syndrome-Role of COX

Not Yet Recruiting
NCT00262470Phase 1

Treatment of Orthostatic Intolerance

Active Not Recruiting
NCT06572917Phase 2

Single-dose Prophylactic INdomethacin in Extremely Preterm Infants

Not Yet Recruiting
NCT06253702Phase 4

Brain Blood Flow Responses to Stress: Sex Differences

Completed
NCT03267680Phase 2

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

Terminated
NCT03713879Phase 3

Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis

Recruiting
NCT03648437Phase 1

Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus

Terminated
NCT04207060Phase 1

Trial of Indomethacin in Chronic Pancreatitis

Completed
NCT04347720

Canadian National PDA Treatment Study

Completed
NCT02609386Phase 2

IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

Completed
NCT05999708Phase 1

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants

Withdrawn
NCT02935205Phase 1

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Unknown
NCT02183168Phase 3

Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis

Completed
NCT02884219Not Applicable

Early Treatment Versus Expectative Management of PDA in Preterm Infants

Completed
NCT01265849Phase 3

Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

Completed

Drug Details

Intervention Type
DRUG
Total Trials
81